Figure 3.

Combined therapy improves glucose tolerance and preserves some functional islets. (A) Mice that remained in remission for 25 weeks post-anti-CD3 monotherapy or combined anti-CD3/ lesogaberan therapies were given an IPGT test. Data shown are mean glucose (mg/dL) over time (minutes) ± SEM of the groups of mice given anti-CD3 monotherapy (solid line and circle symbols) or combined anti-CD3/lesogaberan therapies (dashed line with square symbols). * p = 0.031 for combined therapy versus anti-CD3 monotherapy at 30 min by repeated measures ANOVA. n = 10 mice per group. (B) A representative islet image with few insulin⁺ cells in the mice receiving anti-CD3 (alone) that was co-stained with anti-insulin (green), anti-glucagon (red), and DAPI. (C) A representative islet image with many insulin⁺ cells in the mice receiving combined therapies. Scale bar: 25 µm.